Enzalutamide and lutetium-177–labeled prostate-specific membrane antigen-617 (LuPSMA) have both been proven to improve overall survival (OS) rates in patients with metastatic castration-resistant prostate cancer (mCRPC). Previous research has shown that the effects of androgen and PSMA receptors can complement each other if used concurrently. ...
RLT
Advertisement
Latest News
A CR was observed in the first patient with mCRPC to receive 2 cycles of 67Cu-SAR-bisPSMA at a dosage of 8GBq.
Dr. Ulaner highlights 2 new clinical trials for prostate cancer staging and treatment at Hoag: MIRROR and 177Lu-PNT2002.
The open-label VISON study randomly assigned patients to receive either 177Lu-PSMA-617 plus SoC or SoC alone.
A total of 488 patients received an average of 2 cycles of 225Ac-PSMA RLT between January 2016 and May 2023.
The study analyzed VISION-eligible patients with mCRPC who were classified as TheraP-eligible or ineligible.
The study is the first large-scale report of patients in the United States treated with 177Lu-PSMA-617.
Advertisement
Expert Interviews
Prostate Cancer Knowledge Hubs
Curated clinical content on prostate cancer types, therapies, and technologies
Conference Coverage
Dr. Soon-Shiong provides an overview of the groundbreaking data related to nogapendekin alfa inbakicept for NMIBC.
Dr. Li highlights the significance of adverse pathologic features at radical prostatectomy for AS-eligible patients.
Continuing his discussion at the AUA 2024 Annual Meeting, Dr. Narayan highlights the latest news on nadofaragene firadenovec.
Dr. Narayan breaks down the 5-year follow-up data on nadofaragene firadenovec for patients with BCG-unresponsive NMIBC.
Development of a novel risk score for early intensification approaches to RT or salvage RT for pN1 receiving RP.
Drs. Joyce and Psutka consider patient counseling for adjuvant RCC therapy, and biomarkers and imaging before treatment.
Advertisement
Advertisement
Roundtables
The panel discusses lutetium-177-PSMA for the treatment of advanced prostate cancer and reviews the VISION trial.
Panel experts discuss PSMA-targeting agents currently being assessed, including PSMA-I&T-Lutetium-177.
